GlassScriptPhysician profile
Alexander John Funck
NPI 1720586464
$7,490.51
in general payments reported to CMS, 2019-2025
42 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,369 · 2022: $2,006 · 2023: $459 · 2024: $364 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $1,146.80 | 2021-2022 | |
| Lilly USA, LLC | $588.18 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $566.63 | 2021-2022 | |
| Corcept Therapeutics | $560.61 | 2021-2024 | Korlym |
| Mannkind Corporation | $431.24 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.75 | 2021-2022 | |
| Novo Nordisk INC | $380.51 | 2021-2022 | |
| Abbott Laboratories | $361.78 | 2021-2023 | Freestyle Libre |
| Cequr Corporation | $301.35 | 2022 | |
| Sanofi-Aventis U.S. LLC | $267.57 | 2021-2022 | |
| Dexcom, INC. | $204.38 | 2021-2024 | Dexcom G7 Gss (161) |
| Xeris Pharmaceuticals, INC. | $197.39 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $173.03 | 2021-2022 | |
| Insulet Corporation | $172.70 | 2021-2025 | Omnipod |
| Esperion Therapeutics, INC. | $169.95 | 2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Funck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.